Rosiglitazone increased the risk of heart attack by 16%, heart failure by 23%, and death by 14% compared with pioglitazone.

BBC: Actos is 'alternative' to banned diabetes drug Avandia

In Re: Actos (Pioglitazone) Products Liability Litigation recently surfaced as the newest case to fuel the continuing debate about the use of predictive coding technology in litigation.

FORBES: Guest Post by Matthew Nelson

The FDA will require that GSK develop a restricted access program for Avandia under a risk evaluation and mitigation strategy, or REMS. Under the REMS, Avandia will be available to new patients only if they are unable to achieve glucose control on other medications and are unable to take Actos (pioglitazone), the only other drug in this class.

FORBES: Avandia Saved By The Power of REMS